However, there is no one-size-fits-all approach
They showed up more in the higher-dose groups, were mostly mild to moderate, eased over time, and were the main reason some people left the studies
Here are some key findings: Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Northwestern Now posed five questions to the study senior author Dr
Why is berberine not approved by the FDA
Zahur, M., Tol, J., Bhr, M